Biotech and biopharmaceutical firms struck fewer licensing and acquisition deals in 2012 compared with 2011, perhaps fueled by greater confidence in drug pipelines and fewer worries about patent expirations, according to a new report from EP Vantage. Total licensing-deal value declined 19%, to $20.9 billion, and the number of products licensed dropped from 1,037, to 759. Merger and acquisition deals reached $42.6 billion, down 24%.
Report: Biotech licensing, M&A deals dropped in 2012
SmartBrief Job Listings for Health Care
|NGS Provider Enrollment Rep||
National Government Services - WellPoint
|Program Manager II||
Tufts Health Plan/Network Health
|Director, Medicare Advantage/Medicare Part D Focus||
|Chief, Product Review Branch||
FDA/Center for Biologics Evaluation and Research
|Silver Spring, MD|
|Director of Clinical Research||
Regenesis Biomedical, Inc.